Accurate prognostic indicators are of critical importance for patients with renal cell carcinoma. In this article, the authors argue that the arrival and application of new targeted therapies will necessitate a re-evaluation of the current prognostic systems to incorporate emerging molecular markers with existing clinical and pathologic staging constructs.
- John T Leppert
- Allan J Pantuck
